Pennsylvania Joins $720 Million Opioid Crisis Settlement — Up to $28M Earmarked for Local Recovery Efforts

HARRISBURG — Attorney General Dave Sunday announced that Pennsylvania will receive up to $28 million as part of a sweeping $720 million national settlement involving eight pharmaceutical manufacturers accused of fueling the opioid crisis, largely through the proliferation of highly addictive prescription medications.

The settlement, reached with broad participation from attorneys general across the country, is part of a continued legal effort to hold drug manufacturers accountable for their role in the public health crisis that has devastated communities nationwide.

“Money from this agreement will directly support the counties and communities on the front lines of this epidemic,” said Attorney General Sunday. “These funds will go toward prevention, treatment, and recovery services — where it’s needed most — rather than staying in the pockets of companies that contributed to this devastating crisis.”

Pennsylvania’s Share

The Commonwealth’s potential $28 million payout depends on how many local governments opt in during the upcoming sign-on period. This latest deal follows a landmark $7.4 billion settlement with Purdue Pharma and the Sackler family, from which Pennsylvania is expected to receive up to $200 million.

Companies and Payouts

The eight companies involved and their agreed payments are:

  • Mylan (now Viatris): $284.4 million over nine years

  • Hikma: $95.8 million over one to four years

  • Amneal: $71.7 million over ten years

  • Apotex: $63.6 million in a single-year payment

  • Indivior: $38 million over four years

  • Sun Pharmaceuticals: $30.9 million over one to four years

  • Alvogen: $18.6 million in a single-year payment

  • Zydus: $14.8 million in a single-year payment

Some of the settlements also include non-cash benefits such as free pharmaceutical products or monetary equivalents for distribution in affected communities.

Restrictions and Industry Oversight

Under the terms of the agreement, seven of the eight companies — all except Indivior — have agreed to stop promoting or marketing opioids and are prohibited from manufacturing pills containing more than 40mg of oxycodone. They are also required to implement systems to monitor and report suspicious drug orders.

Indivior, which produces treatments for opioid use disorder, has committed to cease the manufacture and sale of opioid products for the next ten years. However, it may continue marketing and distributing medications designed to treat opioid addiction.

A Continued Effort Amid Ongoing Crisis

While opioid-related deaths slightly declined in Pennsylvania and across the U.S. in 2024, public health experts caution that the situation remains volatile — especially as synthetic opioids such as FYL (fentanyl) and tranquilizers like XYL (xylazine) continue to saturate the illicit drug market.

Naloxone, a life-saving medication that reverses opioid overdoses, remains a critical tool in combating this crisis. Officials continue to encourage widespread distribution and accessibility of Naloxone across high-risk areas.

Attorney General Sunday reiterated the importance of these legal victories, not just for financial restitution, but as a message of accountability. “This is about justice for the thousands of lives lost, and for the families forever impacted by addiction. The road to recovery is long, but this is another important step in making our communities whole again.”

Source: Pennsylvania Attorney General

Back to News